A novel variant of NR5A1, p.R350W implicates potential interactions with unknown co-factors or ligands

Front Endocrinol (Lausanne). 2023 Jan 20:13:1033074. doi: 10.3389/fendo.2022.1033074. eCollection 2022.

Abstract

Introduction: NR5A1 and NR5A2 belong to an orphan nuclear receptor group, and approximately 60% of their amino acid sequences are conserved. Transcriptional regulation of NR5A receptors depends on interactions with co-factors or unidentified ligands.

Purpose and methods: We employed in vitro and in silico analysis for elucidating the pathophysiology of a novel variant in the ligand-binding domain of NR5A1, p.R350W which was identified from a 46,XY patient with atypical genitalia.

Results: In the study, [1] reporter assays demonstrated that R350 is essential for NR5A1; [2] 3D model analysis predicted that R350 interacted with endogenous ligands or unknown cofactors rather than stabilizing the structure; [3] R350 is not conserved in NR5A2 but is specifically required for NR5A1; and [4] none of the 22 known missense variants of the ligand binding domain satisfied all the previous conditions [1]-[3], suggesting the unique role of R350 in NR5A1.

Conclusion: Our data suggest that NR5A1 has unidentified endogenous ligands or co-activators that selectively potentiate the transcriptional function of NR5A1 in vivo.

Keywords: 46,XY DSD; NR5A1; NR5A2; co-factors; ligands; orphan nuclear receptor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Disorder of Sex Development, 46,XY*
  • Humans
  • Ligands
  • Mutation
  • Mutation, Missense
  • Steroidogenic Factor 1 / genetics

Substances

  • Ligands
  • NR5A1 protein, human
  • Steroidogenic Factor 1

Grants and funding

This study was partially supported by a grant from KAKENHI, Kiban (C) (15K09615) funded by the Japan Society for the Promotion of Science (JSPS), to KK. This research was partially supported by the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED under Grant Number JP20am0101111 (support number 2103).